1Department of Biochemistry, Biotechnology and Bioinformatics, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore, 641043, Tamil Nadu, India, 2Redox Regulation Laboratory, Department of Zoology, CBSH, Odisha University of Agriculture and Technology, Bhubaneswar-751003, India
TABLE OF CONTENTS
- 1. Abstract
- 2. Introduction
- 3. Importance of epigenetics in cancers
- 4. Biological basis of cancer
- 4.1. Epigenetic mechanisms in normal cells
- 4.2. Epigenetic mechanisms in cancer cells
- 4.3. Epigenetics of cancer in relation to aging
- 5. DNA methylation
- 5.1. Role of DNA methylation in cancer
- 5.2. DNA hypomethylation in cancer
- 5.3. Epigenetic alterations involving DNA methylation by mutation
- 5.4. DNA hypermethylation in cancer
- 5.5. DNA demethylation
- 6. Histone modifications
- 6.1. Non histone methylation
- 7. Nucleosome remodelling
- 7.1. Changes in chromatin
- 8. Micro RNAs (miRNAs)
- 8.1. miRNA biogenesis
- 8.2. Biological roles of miRNAs
- 9. Regulation of epigenetics in cancer progression
- 10. Role of oxygen and cancer
- 10.1. Normoxia and cancer
- 10.2. Hypoxia
- 10.2.1. Functional effect of epigenetic regulation upon hypoxia
- 10.2.2.. Importance of epigenetics in tumor hypoxia and cancer immunotherapy
- 11. Epigenetic therapy
- 12. Acknowledgments
- 13. References
Genetic and epigenetic modifications in DNA contribute to altered gene expression in aging and cancer. In human cancers, epigenetic changes such as DNA methylation, histone modifications, micro RNAs and nucleosome remodelling all control gene expression. The link between the genetics and epigenetics in cancer is further shown by existence of aberrant metabolism and biochemical pathways in cancer or mutation in genes that are epigenetic players. Reversal of these epigenetic changes has been clearly shown to have therapeutic value in various forms of lymphoma and preleukemia and similar results are appearing for the treatment of solid tumors. In this review, we discuss the functional effects of epigenetic changes inducible by hypoxia, the epigenetic alterations in cancer and how they contribute to tumor progression and their relevance to epigenetic therapy.
2. E. Ballestar. An Introduction to Epigenetics. In: Ballestar E. (eds) Epigenetic Contributions in Autoimmune Disease. Advances in Experimental Medicine and Biology, vol 711. Springer, Boston, MA (2011)
10. N.R. Navis. Organisers and gens (1940) by C. H. Waddington.
13. C. H. Waddington. The strategy of the genes. A Discussion of Some Aspects of Theoretical Biology. London: Allen & Unwin (1957)
41. G.B.N. Chainy, B. Paital, and J. Dandapat. An overview of seasonal changes in oxidative stress and antioxidant defence parameters in some invertebrate and vertebrate species.
46. P. Mishra, B. Paital, S. Jena, S. S. Swain, S. Kumar, M. K. Yadav and L. Samanta. Possible activation of NRF2 by Vitamin E/Curcumin against altered thyroid hormone induced oxidative stress via NFĸB/AKT/mTOR/KEAP1 signalling in rat heart.
47. A. Razin and A. Riggs. DNA methylation and gene function.
48. T. Phillips. The role of methylation in gene expression.
49. R. Straussman, D. Nejman, D. Roberts, I. Steinfeld, B. Blum, N. Benvenisty and H. Cedar. Developmental programming of CpG island methylation profiles in the human genome.
50. L. Laurent, E. Wong, G. Li, T. Huynh, A. Tsirigos, C. T. Ong and C.-L. Wei. Dynamic changes in the human methylome during differentiation.
59. L. Lande-Diner, J. Zhang, I. Ben-Porath, N. Amariglio, I. Keshet, M. Hecht and H. Cedar. Role of DNA Methylation in Stable Gene Repression.
62. P. L. Jones, G. C. Jan Veenstra, P. A. Wade, D. Vermaak, S. U. Kass, N. Landsberger and A.P. Wolffe. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription.
63. X. Nan, H.-H. Ng, C. A. Johnson, C. D. Laherty, B. M. Turner, R.N. Eisenman and A. Bird. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.
66. V. Greger, N. Debus, D. Lohmann, W. Hopping, E. Passarge and B. Horsthemke. Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma.
67. F.M. Kane, M. Loda, M.G. Gaida, J. Lipman, R. Mishra, J. H. Goldman, M. Jessup and R. Kolodner. Methylation of the hMLH1 Promoter Correlates with Lack of Expression of hMLH1 in Sporadic Colon Tumors and Mismatch Repair-defective Human Tumor Cell Lines.
68. C. Stirzaker, DS. Millar, CL. Paul, PM. Warnecke, J. Harrison, PC. Vincent, M. Frommer, SJ. Clark. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors.
69. J.G. Herman, A. Umar, K. Polyak, J.R. Graff, N. Ahuja, J.-P. J Issa and S.B. Baylin. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc National Acad Sci, 95(12), 6870-6875 (1998)
70. T. Furukawa, F. Konishi, S. Masubuchi, K. Shitoh, H. Nagai and T. Tsukamoto. Densely methylatedMLH1 promoter correlates with decreased mRNA expression in sporadic colorectal cancers.
72. S.A. Belinsky, K.J. Nikula, W. A. Palmisano, R. Michels, G. Saccomanno, E. Gabrielson and J.G. Herman. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis.
73. W.H. Lee, R.A. Morton, J.I. Epstein, J.D. Brooks, P.A. Campbell, G.S. Bova and W.G. Nelson. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.
74. M. Makos, B.D. Nelkin, M.I. Lerman, F. Latif, B. Zbar and S.B. Baylin. Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer.
75. B. Vogelstein, E. R. Fearon, S. R. Hamilton, S. E. Kern, A. C. Preisinger, M. Leppert and J. L. Bos. Genetic Alterations during Colorectal-Tumor Development.
77. B.C. Christensen, C.J. Marsit, E.A. Houseman, J.J Godleski, J.L. Longacker, S. Zheng, K.T. Kelsey. Differentiation of Lung Adenocarcinoma, Pleural Mesothelioma, and Nonmalignant Pulmonary Tissues Using DNA Methylation Profiles.
78. M. Toyota, N. Ahuja, M. Ohe-Toyota, J. G. Herman, S. B. Baylin abnd J.-P. J. Issa. CpG island methylator phenotype in colorectal cancer.
82. A. Narayan, W. Ji, X.-Y Zhang, A. Marrogi, J. R. Graff, S. B. Baylin and M. Ehrlich. Hypomethylation of pericentromeric DNA in breast adenocarcinomas.
84. K. D. Hansen, W. Timp, H. C. Bravo, S. Sabunciyan, B. Langmead, O. G. McDonald and A.P. Feinberg. Increased methylation variation in epigenetic domains across cancer types.
85. B. P. Berman, D. J. Weisenberger, J. F. Aman, T. Hinoue, Z. Ramjan, Y. Liu and P. W. Laird. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains.
86. G. C. Hon, R. D. Hawkins, O. L. Caballero, C. Lo, R. Lister, M. Pelizzola and B. Ren. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer.
87. S. A. Bert, M. D. Robinson, D. Strbenac, A. L. Statham, J. Z. Song, T. Hulf and S. J. Clark. Regional Activation of the Cancer Genome by Long-Range Epigenetic Remodeling.
90. A. Spannhoff, A.-T. Hauser, R. Heinke, W. Sippl and M. Jung. The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors.
92. K. M. Bernt, N. Zhu, A. U. Sinha, S. Vempati, J. Faber, A. V. Krivtsov and S. A. Armstrong. MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L.
93. S. R. Daigle, E. J. Olhava, C. A. Therkelsen, C. R. Majer, C.J. Sneeringer, J. Song and R. M. Pollock. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor.
95. N. Azad, C. A. Zahnow, C. M. Rudin and S. B. Baylin. The future of epigenetic therapy in solid tumours-lessons from the past.
97. M. Kulis, S. Heath, M. Bibikova, A. C. Queirós, A. Navarro, G. Clot and J. I. Martín-Subero. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia.
100. Andrew P. Feinberg, Charles W. Gehrke, Kenneth C. Kuo and Melanie Ehrlich. Reduced Genomic 5-Methylcytosine Content in Human Colonic Neoplasia.
101. M. A. Gama-Sosa, V. A. Slagel, R. W. Trewyn, R. Oxenhandler, K. C. Kuo, C. W. Gehrke and M. Ehrlich. The 5-methylcytosine content of DNA from human tumors.
103. C. Mertineit, J.A. Yoder, T. Taketo, D.W. Laird, J.M. Trasler and T.H. Bestor. Sex-specific exons control DNA methyltransferase in mammalian germ cells. Development., 125(5):889-97. (1998)
104. M. Wossidlo, T. Nakamura, K. Lepikhov, C. J. Marques, V. Zakhartchenko and M. Boiani, J. Walter. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming.
105. V. Valinluck and L. C. Sowers. Endogenous Cytosine Damage Products Alter the Site Selectivity of Human DNA Maintenance Methyltransferase DNMT1.
106. Y.-F He, B.-Z. Li, Z. Li, P. Liu, Y. Wang, Q. Tang and G.-L. Xu, Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA.
108. S. Kangaspeska, B. Stride, R. Métivier, M. Polycarpou-Schwarz, D. Ibberson, R. P. Carmouche and G. Reid. Transient cyclical methylation of promoter DNA.
109. R. Métivier, R. Gallais, C. Tiffoche, C. Le Péron, R. Z. Jurkowska, R. P. Carmouche and G. Salbert. Cyclical DNA methylation of a transcriptionally active promoter.
112. J. C. Rice, S. D. Briggs, B. Ueberheide, C. M. Barber, J. Shabanowitz, D. F. Hunt and C. D. Allis. Histone Methyltransferases Direct Different Degrees of Methylation to Define Distinct Chromatin Domains.
117. A. Shilatifard. Chromatin Modifications by Methylation and Ubiquitination: Implications in the Regulation of Gene Expression.
125. C. Dong, Y. Wu, J. Yao, Y. Wang, Y. Yu, P. G. Rychahou and B. P. Zhou. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer.
126. M.-W. Chen, K.-T. Hua, H.-J. Kao, C.-C. Chi, L.-H. G. Wei, Johansson and M.-L. Kuo. H3K9 Histone Methyltransferase G9a Promotes Lung Cancer Invasion and Metastasis by Silencing the Cell Adhesion Molecule Ep-CAM.
127. C. G. Kleer, Q. Cao, S. Varambally, R. Shen, I. Ota, S. A. Tomlins and A. M. Chinnaiyan. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
128. S. Varambally. S. M. Dhanasekaran, M. Zhou, T. R. Barrette, C. Kumar-Sinha, M. G. Sanda and A. M. Chinnaiyan. The polycomb group protein EZH2 is involved in progression of prostate cancer.
129. K. Agger, P. A. C. Cloos, L. Rudkjaer, K. Williams, G. Andersen, J. Christensen and K. Helin. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence.
130. J. S. Song, Y. S. Kim, D.K. Kim, S.I. Park, and S. J. Jang. Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients.
131. Y. Shi, F. Lan, C. Matson, P. Mulligan, J. R. Whetstine, P. A. Cole and Y. Shi. Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1.
133. S. S. Ng, K. L. Kavanagh, M. A. McDonough, D. Butler, E. S. Pilka, B. M. R. Lienard and U. Oppermann. Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity.
134. Y. Okada, G. Scott, M. K. Ray, Y. Mishina and Y. Zhang. Histone demethylase JHDM2A is critical for Tnp1 and Prm1 transcription and spermatogenesis.
135. S. Chuikov, J. K. Kurash, J. R. Wilson, B. Xiao, N. Justin, G. S. Ivanov and D. Reinberg. Regulation of p53 activity through lysine methylation.
136. S. R. Daigle, E. J. Olhava, C. A. Therkelsen, C. R. Majer, C. J. Sneeringer, J. Song and R. M. Pollock. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor.
137. J. Huang, J. Dorsey, S. Chuikov, X. Zhang, T. Jenuwein, D. Reinberg and S. L. Berger. G9a and Glp Methylate Lysine 373 in the Tumor Suppressor p53.
138. E. Kim, M. Kim, D.-H. Woo, Y. Shin, J. Shin, N. Chang and J. Lee. Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells.
139. A. He, X. Shen, Q. Ma, J. Cao, A. von Gise, P. Zhou and W. T. Pu. PRC2 directly methylates GATA4 and represses its transcriptional activity.
140. J.M. Lee, J. S. Lee, H. Kim, K. Kim, H. Park, J.-Y. Kim and S. H. Baek. EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 E3 Ubiquitin Ligase Complex.
141. J. S. Lee, Y. Kim, J. Bhin, H.-J. R. Shin, H. J. Nam, S. H. Lee and S. H. Baek. Hypoxia-induced methylation of a pontin chromatin remodeling factor.
145. R. Stein, A. Razin and H. Cedar.
146. J. E. Dodge, B. H. Ramsahoye, Z. G. Wo, M. Okano and E. Li. De novo methylation of MMLV provirus in embryonic stem cells: CpG versus non-CpG methylation.
147. M. Okano, D. W. Bell, D. A. Haber and E. Li. DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development.
148. M. Tahiliani, K. P. Koh, Y. Shen, W. A. Pastor, H. Bandukwala, Y. Brudno and A. Rao. Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1.
149. R. Lister, M. Pelizzola, R. H. Dowen, R. D. Hawkins, G. Hon, J. Tonti-Filippini and J. R. Ecker. Human DNA methylomes at base resolution show widespread epigenomic differences.
151. B. H. Ramsahoye, D. Biniszkiewicz, F. Lyko, V. Clark, A.P. Bird and R. Jaenisch, Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a.
152. S. Ito, L. Shen, Q. Dai, S. C. Wu, L. B. Collins, J. A. Swenberg and Y. Zhang. Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine.
155. T. J. Ley, T. L. Ding, M. J. Walter, M. D. McLellan, T. Lamprecht, D. E. Larson and R. K. Wilson. DNMT3A Mutations in Acute Myeloid Leukemia.
156. K. Moran-Crusio, L. Reavie, A. Shih, O. Abdel-Wahab, D. Ndiaye-Lobry, C. Lobry and R. L. Levine. Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation.
157. G. Van Haaften, G. L. Dalgliesh, H. Davies, L. Chen, G. Bignell, C. Greenman and J. Teague. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genetics, 41(5), 521-523 (2009)
162. T. Kunej, I. Godnic, J. Ferdin, S. Horvat, P. Dovc and G. A. Calin. Epigenetic regulation of microRNAs in cancer: An integrated review of literature.
163. G. A. Calin, C. D. Dumitru, M. Shimizu, R. Bichi, S. Zupo, E. Noch and C. M. Croce. Nonlinear partial differential equations and applications: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.
164. D. Nass, S. Rosenwald, E. Meiri, S. Gilad, H. Tabibian-Keissar, A. Schlosberg and N. Rosenfeld. MiR-92b and miR-9/9* Are Specifically Expressed in Brain Primary Tumors and Can Be Used to Differentiate Primary from Metastatic Brain Tumors.
165. U. Lehmann, B. Hasemeier, M. Christgen, M. Müller, D. Römermann, F. Länger and H. Kreipe. Epigenetic inactivation of microRNA genehsa-mir-9-1in human breast cancer.
166. Y. Li, Z. Xu, B. Li, Z. Zhang, H. Luo, Y. Wang, X. Wu. Epigenetic silencing of miRNA-9 is correlated with promoter-proximal CpG island hypermethylation in gastric cancer
167. Ye Song, Jiangchao Li, Yinghui Zhu, Yongdong Dai1, Tingting Zeng, Lulu Liu, Jianbiao Li, Hongbo Wang, Yanru Qin, Musheng Zeng, Xin-Yuan Guan and Yan Li. MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma.
168. J. Huang, J. Yu, J. Li, Y. Liu and R. Zhong. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma.
170. C. Neuzillet, A. Tijeras-Raballand, R. Cohen, J. Cros, S. Faivre, E. Raymond and A. de Gramont. Targeting the TGFβ pathway for cancer therapy.
171. D. Lodygin, V. Tarasov, A. Epanchintsev, C. Berking, T. Knyazeva, H. Körner and H. Hermeking. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.
172. H. Kwon, K. Song, C. Han, J. Zhang, N. Ungerleider, L. Yao, and T. Wu. Epigenetic silencing of microRNA-34a in human cholangiocarcinoma cells via DNA methylation and EZH2: Impact on regulation of Notch pathway.
173. Y. Xie, P. Zong, W. Wang, D. Liu, B. Li, Y. Wang and F. Li. Hypermethylation of potential tumor suppressor miR-34b/c is correlated with late clinical stage in patients with soft tissue sarcomas.
174. F. Balaguer, A. Link, J. J. Lozano, M. Cuatrecasas, T. Nagasaka, C. R. Boland and A. Goel. Epigenetic Silencing of miR-137 Is an Early Event in Colorectal Carcinogenesis.
175. Y. Deng, H. Deng, F. Bi, J. Liu, L. T. Bemis, D. Norris and Q. Zhang. MicroRNA-137 Targets Carboxyl-terminal Binding Protein 1 in Melanoma Cell Lines.
176. Y. Zhao, Y. Li, G. Lou, L. Zhao, Z. Xu, Y. Zhang & F. He. MiR-137 Targets Estrogen-Related Receptor Alpha and Impairs the Proliferative and Migratory Capacity of Breast Cancer Cells.
177. X. Zhu, Y. Li, H. Shen, H. Li, L. Long, L. Hui & W. Xu. miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6.
179. W. Li, H. Huang, J. Su, X. Ji, X. Zhang, Z. Zhang and H. Wang. RETRACTED ARTICLE: miR-124 Acts as a Tumor Suppressor in Glioblastoma via the Inhibition of Signal Transducer and Activator of Transcription 3.
180. B. Zeng, Z. Li, R. Chen, N. Guo, J. Zhou, Q. Zhou and Y. Gong. Epigenetic regulation of miR-124 by Hepatitis C Virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3.
182. J. S. Lee, Y. Kim, I. S. Kim, B. Kim, H. J. Choi, J. M. Lee and S. H. Baek. Negative Regulation of Hypoxic Responses via Induced Reptin Methylation.
184. D. R. Borger, L. C. Gavrilescu, M. C. Bucur, M. Ivan and J. A. DeCaprio. AMP-activated protein kinase is essential for survival in chronic hypoxia.
185. R. Fukuda, H. Zhang, J. Kim, L. Shimoda, C. V. Dang G. L. Semenza. HIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells.
189. M. Ema, S. Taya, N. Yokotani, K. Sogawa, Y. Matsuda and Y. Fujii-Kuriyama. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 regulates the VEGF expression and is potentially involved in lung and vascular development.
190. G. L. Semenza and G. L. Wang. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation.
191. C. Dong, Y. Wu, J. Yao, Y. Wang, Y. Yu, P. G. Rychahou and B. P. Zhou. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer.
192. S. Salceda and J. Caro. Hypoxia-inducible Factor 1α (HIF-1α) Protein Is Rapidly Degraded by the Ubiquitin-Proteasome System under Normoxic Conditions.
193. S. V. Ivanov, K. Salnikow, A.V. Ivanova, L. Bai and M. I. Lerman. Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13.
194. H. Chen, Y. Yan, T. L. Davidson, Y. Shinkai and M. Costa. Hypoxic Stress Induces Dimethylated Histone H3 Lysine 9 through Histone Methyltransferase G9a in Mammalian Cells.
196. Z. Wang, D. Yang, X. Zhang, T. Li, J. Li, Y. Tang and W. Le. Hypoxia-Induced Down-Regulation of Neprilysin by Histone Modification in Mouse Primary Cortical and Hippocampal Neurons.
200. B. Paital, A. Bal, A. G. Rivera-Ingraham and J.-H. Lignot. Increasing frequency of large-scale die-off events in the Bay of Bengal: reasoning, perceptive and future approaches. Ind J Geo-Mar Sci, 47(11), 2135-2146 (2018) nopr.niscair.res.in/handle/123456789/45314
201. B. Paital, D. Guru, P. Mohapatra, B. Panda, N. Parida, S. Rath and A. Srivastava. Ecotoxic impact assessment of graphene oxide on lipid peroxidation at mitochondrial level and redox modulation in fresh water fish
202. R. Sullivan, G. C. Pare, L. J. Frederiksen, G. L. Semenza and C. H. Graham. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity.
203. M. Mohme, S. Riethdorf and K. Pantel. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.
205. G. Fluegen, A. Avivar-Valderas, Y. Wang, M. R. Padgen, J. K. Williams, A. R. Nobre and J. A. Aguirre-Ghiso. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments.
206. M. S. Sosa, F. Parikh, A. G. Maia, Y. Estrada, A. Bosch, P. Bragado and J. A. Aguirre-Ghiso. NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.
207. D. S. Das, A. Ray, A. Das, Y. Song, Z. Tian, B. Oronsky and K. C. Anderson. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
211. A. Ohta, R. Diwanji, R. Kini, M. Subramanian, A. Ohta and M. Sitkovsky.
212. J. Sceneay, M. T. Chow, A. Chen, H. M. Halse, C. S. F. Wong, D. M. Andrews and A. Möller. Primary Tumor Hypoxia Recruits CD11b+/Ly6Cmed/Ly6G+Immune Suppressor Cells and Compromises NK Cell Cytotoxicity in the Premetastatic Niche.
213. C.A. Corzo, T. Lu, L. Condamine, M. J. Cotter, J.-I. Youn, P. Cheng and D.I. Gabrilovich. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.
214. M. Z. Noman, G. Desantis, B. Janji, M. Hasmim, S. Karray, P. Dessen and S. Chouaib. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
215. K. E. Pauken, M. A. Sammons, P. M. Odorizzi, S. Manne, J. Godec, O. Khan and E. J. Wherry. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.
216. D. R. Sen, J. Kaminski, R. A. Barnitz, M. Kurachi, U. Gerdemann, K. B. Yates and W. N. Haining. The epigenetic landscape of T cell exhaustion.
217. F. Falahi, M. van Kruchten, N. Martinet, G. Hospers and M. G. Rots. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
218. L. Sigalotti, E. Fratta, S. Coral, and M. Maio. Epigenetic drugs as immunomodulators for combination therapies in solid tumors.
219. M. Maio, A. Covre, E. Fratta, A. M. Di Giacomo, P. Taverna, P. G. Natali and L. Sigalotti. Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy.
221. C. S. Tellez, M. J. Grimes, M. A. Picchi, Y. Liu, T. H. March, M. D. Reed and S. A. Belinsky. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.
225. S. R. Daigle, E. J. Olhava, C. A. Therkelsen, C. R. Majer, C. J. Sneeringer, J. Song and R. M. Pollock. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor.
227. S. Wee, D. Dhanak, H. Li, S. A. Armstrong, R. A. Copeland, R. Sims and L. Schweizer. Targeting epigenetic regulators for cancer therapy.
228. J. Tan, X. Yang, L. Zhuang, X. Jiang, W. Chen, P. L. Lee and Q. Yu. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
232. J. E. Delmore, G. C. Issa, M. E. Lemieux, P. B. Rahl, J. Shi, H. M. Jacobs and C. S. Mitsiades. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc.
234. M. Esteller, J. Garcia-Foncillas, E. Andion, S. N. Goodman, O. F. Hidalgo, V. Vanaclocha and J. G. Herman. Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents.
235. Y. Li, Y. Yang, Y. Lu, J. G. Herman, M. V. Brock, P. Zhao and M. Guo. Predictive value of CHFR and MLH1 methylation in human gastric cancer.
236. T. Taniguchi, M. Tischkowitz, N. Ameziane, S. V. Hodgson, C. G. Mathew, H. Joenje and A. D. D'Andrea. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
237. M. Tanaka, P. Chang, Y. Li, D. Li, M. Overman and D. M. Maru, C. Eng. Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer.
238. J. Veeck, S. Ropero, F. Setien, E. Gonzalez-Suarez, A. Osorio, J. Benitez and M. Esteller. BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly (Adenosine Diphosphate) - Ribose Polymerase Inhibitors.
239. G. Strathdee, M. J. MacKean, M. Illand and R. Brown. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
240. E. Dejeux, J. Rønneberg, H. Solvang, I. Bukholm, S. Geisler, T. Aas and J. Tost. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.
241. J.-H Lee, M.-J Kang, H.-Y Han, M.-G Lee, S.-I. Jeong, B.-K Ryu and S.-G Chi. Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNF -Induced Apoptosis.
242. J. L. Ramirez, R. Rosell, M. Taron, M. Sanchez-Ronco, V. Alberola, R. de las Peñas and S. Catot. 14-3-3σ Methylation in Pre-treatment Serum Circulating DNA of Cisplatin-Plus-Gemcitabine-Treated Advanced Non-Small-Cell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer Group.
243. M. P.A. Ebert, M. Tänzer, B. Balluff, E. Burgermeister, A. K. Kretzschmar, D. J. Hughes and R. M. Schmid. TFAP2E-DKK4and Chemoresistance in Colorectal Cancer.
244. V. F. Chekhun, G. I. Kulik, O. V. Yurchenko, V. P. Tryndyak, I. N. Todor, L. S. Luniv and I.P. Pogribny. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.
245. M. S. Soengas, P. Capodieci, D. Polsky, J. Mora, M. Esteller, X. Opitz-Araya and S. W. Lowe. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma.
246. E. Iorns, N. C. Turner, R. Elliott, N. Syed, O. Garrone, M. Gasco and A. Ashworth. Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer.
247. I. Ibanez de Caceres, M. Cortes-Sempere, C. Moratilla, R. Machado-Pinilla, V. Rodriguez-Fanjul, C. Manguán-García and R. Perona. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
248. Faller, J. William Rafferty, Mairin, Hegarty, Shauna, Gremel, Gabriela, Ryan, Denise, Fraga, F. Mario Esteller, Manel, Dervan, A. Peter Gallagher and M. William. Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis.
249. L. Ai, W.-J. Kim, B. Demircan, L. M. Dyer, K. J. Bray, R. R. Skehan and K. D. Brown. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
250. L. Shen, Y. Kondo, S. Ahmed, Y. Boumber, K. Konishi, Y. Guo and J.-P. J. Issa. Drug Sensitivity Prediction by CpG Island Methylation Profile in the NCI-60 Cancer Cell Line Panel.
Key Words: Epigenetics, Cancer, Hypoxia, DNA Methylation, Histone Modifications, miRNAs, Chromatin.
Send correspondence to: Ramalingam Nirmaladevi, Department of Biochemistry, Biotechnology and Bioinformatics, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore, 641043, Tamil Nadu, India, Tel.: 91-9976152000, E-mail: firstname.lastname@example.org